Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induces by dextran sulphate sodium

Journal of Pathology

Volumn 209, Issue 3, 2006, Pages 376-383

  Kobayashi, K ^a   Arimura, Y ^a   Goto, A ^a   Okahara, S ^a   Endo, T ^a   Shinomura, Y ^a   Imai, K ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

DSS colitis; Matrix metalloproteinases; siRNA; Stromelysins

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DEXTRAN SULFATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEASOME INHIBITOR; SMALL INTERFERING RNA; STROMELYSIN; STROMELYSIN 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; ENZYME INHIBITION; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UNCERTAINTY; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY;

ANIMALS; COLITIS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FEMALE; IMIDAZOLES; INFLAMMATORY BOWEL DISEASES; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; PYRIDINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745698756     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1978     Document Type: Article

References (37)

1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
2. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21694.
3. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 2001;17:463-516.
4. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
5. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149.
6. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, Kere J, Saarialho-Kere U. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol 1998; 152:1005 -1014.
7. Von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63-73.
8. Louis E, Ribbens C, Godon A, Franchimont D, De Groote D, Hardy N, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000;120:241-246.
9. Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:1535-1542.
10. Di Sebastiano P, di Mola FF, Artesed L, Rossi C, Mascetta G, Pernthaler H, et al. Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 2001;63:234-239.
11. Naito Y, Takagi T, Kuroda M, Katada K, Ichikawa H, Kokura S, et al. An orally active matrix metalloproteinase inhibitor, ONO-817, reduces dextran sulphate sodium-induced colitis in mice. InflammRres 2004;53:462-468.
12. Medina C, Videla S, Radomski A, Radomski MW, Antolín M, Guarner F, et al. Therapeutic effect of phenantroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol 2001;36:1314-1319.
13. Medina C, Videla S, Radomski A, Radomski MW, Antolín M, Guarner F, et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 2003;284:G116-G122.
14. Medina C, Santana A, Llopis M, Paz-Cabrera MC, Antolín M, Mourelle M, et al. Induction of colitis transmural inflammation by bacteroides fragilis. Inflamm Bowel Dis 2005;11:99-105.
15. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005;23:842-849.
16. Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997;158:1582-1590.
17. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003;162:1355-1360.
18. Atula S, Grenman R, Syrjanen S. Fibroblasts can modulate the phenotype of malignant epithelial cells in vitro. Exp Cell Res 1997;235:180-187.
19. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut 2002;50:507-512.
20. Jainchill JL, Aaronson SA, Todaro GJ. Murine sarcoma and leukemia viruses: assay using clonal lines of contact-inhibited mouse cells. J Virol 1969;4:549-553.
21. Puck TT, Cieciura SJ, Robinson A. Genetics of somatic mammalian cells III. Long-term cultivation of euploid cells from human and animal subjects. J Exp Med 1958;108:945-956.
22. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-750.
23. Gautschi O, Tschopp S, Olie RA, Leech SH, Simoes-Wust AP, Ziegler A, et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001;93:463-471.
24. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002;36:850-860.
25. Nakamura S, Goto J, Kitayama M, Kino I. Application of the crypt-isolation technique to flow-cytometric analysis of DNA content in colorectal neoplasms. Gastroenterology 1994; 106:100-107.
26. Grossmann J, Maxson JM, Whitacre CM, Orosz DE, Berger NA, Fiocchi C, et al. New isolation technique to study apoptosis in human intestinal epithelial cells. Am J Pathol 1998;153:53-62.
27. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, Radomski MW, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 1999;82:1730-1735.
28. Radomski A, Sawicki G, Olson DM, Radomski MW. The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br J Pharmacol 1998;125:1455-1462.
29. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-498.
30. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-1300.
31. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003;63:3919-3922.
32. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327:761-766.
33. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002;32:107-108.
34. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay M. RNA interference in adult mice. Nature 2002;418:38-39.
35. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737-747.
36. Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667-671.
37. Skobe M, Fusenig NE. Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 1998;95:1050-1055.